Cat. No.: HY-L074

Anti-Breast Cancer Compound Library

83 Cited Publications

Customer Review

Based on 83 publication(s) in Google Scholar

Breast cancer is the most frequent cancer among women, impacting 2.1 million women each year, and also causes the greatest number of cancer-related deaths among women. Surgery is usually the first type of treatment for breast cancer, which is usually followed by chemotherapy or radiotherapy or, in some cases, hormone or targeted therapies, especially for metastatic breast cancer (MBC).

Breast cancer is a heterogeneous disease, which is categorized into 3 major subtypes based on the presence or absence of molecular markers for estrogen or progesterone receptors and human epidermal growth factor 2 (ERBB2; formerly HER2): hormone receptor positive/ERBB2 negative (70% of patients), ERBB2 positive (15%-20%), and triple-negative (tumors lacking all 3 standard molecular markers; 15%). Different intrinsic subtypes exhibit different tumor behavior with different prognoses, and may require specific targeted therapies to maximize treatment effectiveness. Otherwise, some signaling pathways also play important roles in the development of breast cancer, such as NF-κB Signaling Pathway, TGF-beta Signaling Pathway, PI3K/AKT/mTOR signaling pathway and Notch Signaling Pathway. These signaling pathways offer ideal targets for development of new targeted therapies for breast cancer.

MCE supplies a unique collection of 3,365 compounds with identified and potential anti-breast cancer activity. MCE Anti-Breast Cancer Compound Library is a useful tool for anti-breast cancer drugs screening.

For pre-dissolved solutions, 10 mM for compounds with the solubility not lower than 10 mM, 2 mM for compounds with solubility between 2 mM and 10 mM, and 3 mg/mL for compounds with unconfirmed molecular weight and solubility not lower than 3 mg/mL.

PDF
Excel
SDF
Manual

Size

Price

Stock

Quantity

In-stock

(2-3 weeks)

Get a Quotation Now

In-stock

(2-3 weeks)

Get a Quotation Now

(2-3 weeks)

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Description & Advantages
Product Details
- Formulation
- Layout
- Container
- Storage
- Shipping
Publications (83)
Documentation
Composition

Description & Advantages

• A unique collection of 3,365 compounds with identified and potential anti-breast cancer activity for high throughput screening (HTS) and high content screening (HCS).

• Targets include kinases, cell cycle key components, tumorigenesis related signaling pathways, popular targets in breast cancer, and more.

• A useful tool for the discovery of anti-breast cancer drugs.

• Bioactivity and safety confirmed by preclinical research and clinical trials. Some have been approved by FDA.

• Structurally diverse, medicinally active, and cell permeable.

• Detailed compound information with structure, IC₅₀, and brief introduction.

• Validated NMR and HPLC to ensure high purity and quality.

• All compounds are in stock and continuously updated.

Product Details

Formulation

A collection of 3,365 small molecules with anti-breast cancer activity supplied as pre-dissolved Solutions or Solid

Solution: 3,249 compounds supplied in 10 mM solution, 110 compounds supplied in 2 mM solution, 6 compounds supplied in 3 mg/mL solution.

Layout

96-well storage tube or 96-well plate: 1st and 12th column are left empty.
384-well plate: the first two columns and the last two columns are left empty.
Compounds with different concentrations or dissolved in different solvents will be put on separate plates.
This way of layout may increase the number of plates because there could be three solvents and three concentrations.
If you have other requirements, please let us know.

Container

96- or 384-well Plate with Peelable Foil Seal; 96-well Format Sample Storage Tube With Screw Cap and Optional 2D Barcode

Storage

-80°C

Shipping

Blue ice or dry ice